{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"193-521-552-731-286","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"193-521-552-731-286"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11624,"type":"PATENT","title":"Mayo Medical School - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5667,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8299,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: mayo medi*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5671
Search Applicants and Owners separately:univ* AND Mainz. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1203
Search Applicants and Owners separately: mayo medi*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5671
Search Applicants and Owners separately:univ* AND Mainz. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1203
administering to said cells or tissues an Aβ42-reducing effective amount of an NSAID, or a structural derivative or analogue thereof, which reduces the level of Aβ42 in said cells or tissues."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the level of Aβ38 is increased."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein levels of one or more of Aβ34, Aβ36, Aβ37, and Aβ39 are increased."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the level of Aβ40 is unchanged."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said NSAID or structural derivative or analogue is an aryl propionic acid or a pharmaceutically acceptable salt or ester thereof."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said NSAID is selected from the group consisting of flufenamic acid, fenoprofen, sulindac sulfate, indomethacin, mefenamic acid, ibuprofen, and flurbiprofen, and pharmaceutically acceptable salts or esters thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said NSAID, or structural derivative or analogue thereof, lacks the ability to inhibit COX-1, COX-2, or both COX-1 and COX-2 activity."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said Aβ42 level in or secreted from said cells or tissues is monitored."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method of reducing the level of Aβ42 in a mammal, comprising the steps of:\n
identifying a mammal in need of a reduction in Aβ42 levels; and\n
administering to said mammal an Aβ42-reducing effective amount of an NSAID, or structural derivative or analogue thereof, which reduces the level of Aβ42."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the level of Aβ38 is increased."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein levels of one or more of Aβ34, Aβ36, Aβ37, and Aβ39 are increased."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the level of Aβ40 is unchanged."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID or structural derivative or analogue is an aryl propionic acid or a pharmaceutically acceptable salt or ester thereof."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID is selected from the group consisting of flufenamic acid, fenoprofen, sulindac sulfate, indomethacin, mefenamic acid, ibuprofen, and flurbiprofen, or a pharmaceutically acceptable salt or ester thereof."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID, or structural derivative or analogue thereof, lacks the ability to inhibit COX-1, COX-2, or both COX-1 and COX-2 inhibiting activity."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said mammal is a human."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said mammal has not been diagnosed with Alzheimer's disease."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said mammal does not have a genetic predisposition for Alzheimer's disease."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said Aβ42 level is monitored in said mammal."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID is flubiprofen or a pharmaceutically acceptable salt or ester thereof."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID is sulindac sulfate or a pharmaceutically acceptable salt or ester thereof."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said NSAID is indomethacin or a pharmaceutically acceptable salt or ester thereof."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said aryl propioinic acid is a S-enantiomer."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said aryl propionic acid is a R-enantiomer."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said aryl propioinic acid is a racemate."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A method of reducing the level of Aβ42 in a mammal, comprising steps of:\n
identifying a mammal in need of a reduction in Aβ42 levels;\n
selecting an NSAID, or a structural derivative or analogue thereof, that can reduce Aβ42 levels; and administering to said mammal an Aβ42 -reducing effective amount of NSAID, or a structural derivative or analogue thereof."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said NSAID is flurbiprofen or a pharmaceutically acceptable salt or ester thereof."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein said NSAID is flurbiprofen or a pharmaceutically acceptable salt or ester thereof."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["A method of reducing the level of Aβ42 in mammalian cells or tissues, comprising the steps of:\n
administering to said cells or tissues an Aβ42 -reducing effective amount of R- flurbiprofen or a pharmaceutically acceptable salt or ester thereof that reduces the level of Aβ42 in said cells or tissues."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A new method of reducing the level of Aβ42 in a mammal, comprising the steps of:\n
identifying a mammal in need of a reduction in Aβ42 levels; and administering to said mammal an Aβ42 -reducing effective amoaunt of R- flurbiprofen or a pharmaceutically acceptable salt or ester thereof that reduces the level of Aβ42 ."],"number":30,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}